AMENDMENT TO THE CLAIMS

Please **cancel** claims 35-40, 60-62, 66 and 67.

Please **amend** the claims as follows:

1. (Currently Amended) ~~A~~ An isolated tolerogenic dendritic cell comprising an oligodeoxyribonucleotide having one or more NF-κB binding sites, wherein the NF-κB binding sites inhibit NF-κB transcriptional activity.

2. (Currently Amended) The isolated tolerogenic dendritic cell of claim 1 wherein the oligodeoxyribonucleotide sequence has two NF-κB binding sites.

3. (Currently Amended) The isolated tolerogenic dendritic cell of claim 1 wherein the oligodeoxyribonucleotide has the sequence set forth by SEQ ID NO:1.

4. (Currently Amended) The isolated tolerogenic dendritic cell of claim 1 further comprising a viral vector.

5. (Currently Amended) The isolated tolerogenic dendritic cell of claim 4 wherein the viral vector is derived from a virus selected from the group consisting of adenovirus, adeno-associated virus, retrovirus and herpes virus.

6. (Currently Amended) The isolated tolerogenic dendritic cell of claim 5 wherein the viral vector is derived from adenovirus.

7. (Currently Amended) A method of producing ~~a~~ an isolated tolerogenic dendritic cell comprising (a) propagating immature isolated dendritic cells from a mammalian donor, (b) incubating the isolated dendritic cells with an oligodeoxyribonucleotide having at least one NF-κB binding site under conditions wherein the isolated dendritic cells internalize the oligodeoxyribonucleotide, wherein the NF-κB binding sites inhibit NF-κB transcriptional activity and (c) culturing said isolated dendritic cells.

8. (Original) The method of claim 7 wherein the oligodeoxyribonucleotide has the sequence set forth in SEQ ID NO:1.

9. (Currently Amended) The method of claim 7 further comprising incubating the isolated dendritic cells in the presence of one or more cytokines.

10. (Original) The method of claim 9 wherein the cytokine is GM-CSF.

11. (Currently Amended) The method of claim 9 further comprising incubating the isolated dendritic cells in the presence of TGF-β.

12. (Currently Amended) The method of claim 7 further comprising infecting said isolated tolerogenic dendritic cells with a viral vector.

13. (Original) The method of claim 12 wherein the viral vector is derived from a virus selected from the group consisting of adenovirus, adeno-associated virus, retrovirus and herpes virus.

14. (Original) The method of claim 13 wherein the viral vector is derived from adenovirus.

15. (Currently Amended) A method for enhancing tolerogenicity in a mammalian host comprising (a) propagating immature isolated dendritic cells from a mammalian donor, (b) incubating the isolated dendritic cells with an oligodeoxyribonucleotide having at least one NF-κB binding site under conditions wherein the dendritic cells internalize the oligodeoxyribonucleotide, wherein the NF-κB binding sites inhibit NF-κB transcriptional activity (c) culturing said isolated dendritic cells, and (d) administering said isolated tolerogenic dendritic cells to said host.

16. (Original) The method of claim 15 wherein the oligodeoxyribonucleotide has the sequence set forth in SEQ ID NO:1.

17. (Original) The method of claim 15 further comprising incubating said dendritic cells in the presence of one or more cytokines.

18. (Original) The method of claim 17 wherein the cytokine is GM-CSF.

19. (Original) The method of claim 16 further comprising incubating said dendritic cells in the presence of TGF-β.

20. (Original) The method of claim 15 further comprising infecting said tolerogenic dendritic cells with a viral vector before administering the cells to said host.

21. (Original) The method of claim 20 wherein the viral vector is derived from a virus selected from the group consisting of adenovirus, adeno-associated virus, retrovirus and herpes virus.

22. (Original) The method of claim 21 wherein the viral vector is derived from adenovirus.

23. (Original) The method of claim 15 further comprising administering FK 506 to the host.

24. (Original) The method of claim 15 further comprising administering cyclosporine A to the host.

25. (Original) The method of claim 15 further comprising administering FK 506 and cyclosporine A to the host.

26. (Currently Amended) The method of ~~claims~~ claim 15~~, and~~ or 20 wherein the tolerogenic dendritic cells are administered to the host intravenously.

27. (Original) The method of claim 15 wherein the host is a transplant host.

28. (Original) The method of claim 15 wherein the host has an inflammatory related disease.

29. (Original) The method of claim 28 wherein the host has arthritis.

30. (Original) A kit for enhancing tolerogenicity in a mammalian host comprising tolerogenic dendritic cells which comprise an oligodeoxyribonucleotide having at least one NF-κB binding site, wherein the NF-κB binding sites inhibit NF-κB transcriptional activity.

31. (Original) The kit of claim 30 wherein the oligodeoxyribonucleotide has the sequence set forth in SEQ ID NO:1.

32. (Original) The kit of claim 30 wherein the tolerogenic dendritic cells further comprise a viral vector.

33. (Original) The kit of claim 32 wherein the viral vector is derived from a virus selected from the group consisting of adenovirus, adeno-associated virus, retrovirus and herpes virus.

34. (Original) The kit of claim 33 wherein the viral vector is derived from adenovirus.

35-40. (Cancelled)

41. (Currently Amended) ~~A~~ An isolated tolerogenic dendritic cell comprising an oligodeoxyribonucleotide comprising at least one NFκB binding site having the sequence set forth by SEQ ID NO:1, wherein the NF-κB binding sites inhibit NF-κB transcriptional activity.

42. (Currently Amended) The isolated tolerogenic dendritic cell of claim 41 further comprising an adenovirus vector.

43. (Currently Amended) A method of producing ~~a~~ an isolated tolerogenic dendritic cell comprising (a) propagating immature isolated dendritic cells from a mammalian donor, (b) incubating the isolated dendritic cells with an oligodeoxyribonucleotide comprising at least one NFκB binding site and having the sequence set forth in SEQ ID NO:1 under conditions wherein the isolated dendritic cells internalize the oligodeoxyribonucleotide, wherein the NF-κB binding sites inhibit NF-κB transcriptional activity and (c) culturing said isolated dendritic cells.

44. (Currently Amended) The method of claim 43 further comprising incubating the isolated dendritic cells in the presence of one or more cytokines.

45. (Original) The method of claim 44 wherein the cytokine is GM-CSF.

46. (Currently Amended) The method of claim 44 further comprising incubating the isolated dendritic cells in the presence of TGF-β.

47. (Currently Amended) The method of claim 43 further comprising infecting said isolated tolerogenic dendritic cells with viral vector.

48. (Original) The method of claim 47 wherein the viral vector is derived from adenovirus.

49. (Currently Amended) A method for enhancing tolerogenicity in a mammalian host comprising (a) propagating immature isolated dendritic cells from a mammalian donor, (b) incubating the isolated dendritic cells with an oligodeoxyribonucleotide comprising at least one NFkB binding site and having the sequence set forth in SEQ ID NO:1 under conditions wherein the isolated dendritic cells internalize the oligodeoxyribonucleotide, wherein the NF-κB binding sites inhibit NF-κB transcriptional activity (c) culturing said isolated dendritic cells, and (d) administering said tolerogenic isolated dendritic cells to said host.

50. (Original) The method of claim 49 further comprising incubating said dendritic cells in the presence of one or more cytokines.

51. (Original) The method of claim 50 wherein the cytokine is GM-CSF.

52. (Original) The method of claim 50 further comprising incubating said dendritic cells in the presence of TGF-β.

53. (Original) The method of claim 49 further comprising infecting said tolerogenic dendritic cells with a viral vector before administering the cells to said host.

54. (Original) The method of claim 53 wherein the viral vector is derived from adenovirus.

55. (Original) The method of claim 49 further comprising administering FK 506 to the host.

56. (Original) The method of claim 49 further comprising administering cyclosporine A to the host.

57. (Original) The method of claim 49 further comprising administering FK 506 and cyclosporine A to the host.

58. (Original) The method of claim 49 wherein the tolerogenic dendritic cells are administered to the host intravenously.

59. (Original) The method of claim 49 wherein the host is a transplant host.

60-62. (Cancelled)

63. (Original) A kit for enhancing tolerogenicity in a mammalian host comprising tolerogenic dendritic cells which comprise an oligodeoxyribonucleotide comprising at least one NFkB binding site and having the sequence set forth in SEQ ID NO:1, wherein the NF-κB binding sites inhibit NF-κB transcriptional activity.

64. (Original) The kit of claim 63 further comprising a viral vector.

65. (Original) The kit of claim 64 wherein the viral vector is derived from adenovirus.

66-67. (Cancelled)